We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-13.34%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.15B
AUM Growth
-$354M
Cap. Flow
+$252M
Cap. Flow %
11.69%
Top 10 Hldgs %
47.71%
Holding
76
New
9
Increased
16
Reduced
38
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$76.6M
2
XLRN
Acceleron Pharma
XLRN
+$64.1M
3
AGEN
Agenus
AGEN
+$39M
4
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$30.8M
5
BEAM icon
Beam Therapeutics
BEAM
+$17.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$63.6M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$38.8M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$19.5M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$19.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSP icon
51
Inspire Medical Systems
INSP
$1.74B
$9.04M 0.42%
150,000
-22,300
-13% -$1.65M
ALLK
52
DELISTED
Allakos
ALLK
$8.9M 0.41%
200,000
-100,000
-33% -$6.84M
KURA icon
53
Kura Oncology
KURA
$850M
$7.96M 0.37%
800,000
-200,000
-20% -$2.29M
HARP
54
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$7.53M 0.35%
64,999
– –
MRUS
55
DELISTED
Merus
MRUS
$7.26M 0.34%
600,000
-400,000
-40% -$6.33M
INSM icon
56
Insmed
INSM
$28.6B
$5.81M 0.27%
+362,273
New +$8.59M
EIGR
57
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5.54M 0.26%
27,171
-609
-2% -$194K
BCEL
58
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.4M 0.25%
326,139
-2
-0% -$36
TECX
59
Tectonic Therapeutic
TECX
$606M
$4.94M 0.23%
26,465
– –
ARNA
60
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.2M 0.2%
100,000
-72,300
-42% -$3.31M
NERV icon
61
Minerva Neurosciences
NERV
$199M
$3.66M 0.17%
75,988
– –
AMRN
62
Amarin Corp
AMRN
$303M
$3.6M 0.17%
45,000
-20,000
-31% -$6.64M
ARCT icon
63
Arcturus Therapeutics
ARCT
$211M
$3.56M 0.17%
+262,037
New +$3.35M
XFOR icon
64
X4 Pharmaceuticals
XFOR
$460M
$3.42M 0.16%
11,387
+2,962
+35% +$840K
AUTL
65
Autolus Therapeutics
AUTL
$562M
$2.88M 0.13%
479,988
– –
NKTR icon
66
Nektar Therapeutics
NKTR
$2.58B
$2.68M 0.12%
10,000
-3,333
-25% -$1.03M
TBPH icon
67
Theravance Biopharma
TBPH
$877M
$2.31M 0.11%
100,000
+50,000
+100% +$1.25M
NBIX icon
68
Neurocrine Biosciences
NBIX
$16.6B
$2.16M 0.1%
25,000
-14,300
-36% -$1.4M
DTIL icon
69
Precision BioSciences
DTIL
$207M
$2.09M 0.1%
11,551
-4,033
-26% -$1.06M
GOSS icon
70
Gossamer Bio
GOSS
$87M
$2.01M 0.09%
198,382
-101,618
-34% -$1.33M
ORTX
71
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.93M 0.09%
25,665
-9,355
-27% -$1.08M
FATE icon
72
Fate Therapeutics
FATE
$326M
$1.67M 0.08%
+75,000
New +$1.9M
OTLKW
73
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$65K ﹤0.01%
416,666
– –
XBI icon
74
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-500,000
Closed -$47.6M
RARX
75
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-295,600
Closed -$13.9M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Cormorant Asset Management held 76 positions worth $2.15B, down 14% from $2.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $252M of net new capital in Q1 2020, opening 9 new positions and adding to 16 existing holdings. Its largest new stake was Revolution Medicines: 2,767,078 shares worth $60.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $63.6M trimmed.

  • Cormorant Asset Management's largest Q1 2020 buy was Revolution Medicines: 2,767,078 shares worth $60.6M.
  • Cormorant Asset Management added most to Eidos Therapeutics, Inc. Common Stock in Q1 2020, an estimated $30.8M increase.
  • Cormorant Asset Management's biggest Q1 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $63.6M.
  • Cormorant Asset Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q1 2020, selling an estimated $13.9M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $2.15B portfolio in Q1 2020.
  • Cormorant Asset Management opened 9 new positions and closed 3 in Q1 2020.
  • Cormorant Asset Management's portfolio value fell 14% quarter-over-quarter to $2.15B.

Based on Cormorant Asset Management's 13F filing for Q1 2020, filed 15 May 2020.